Harnessing Invariant NKT Cells as a Novel Therapeutic Platform for Blood Cancers
Time: 2:00 pm
day: Day One
Details:
• Evaluating the superior anti-tumour potency of engineered iNKT cells vs T-cells against
B-cell lymphoma
• Developing iNKT cell immunotherapies targeting novel antigens beyond CD19 for
multiple myeloma
• Assessing opportunities and challenges in clinically translating engineered iNKT cell
therapies
